eMedI Chat
 eMedI Chat

ONCOLOGY PIPELINE AGENTS

Please note that this page may contain information on EMD Serono, Inc. marketed and/or investigational products. Investigational agents and investigational indications for marketed products are under clinical investigation and have not been proven to be safe and effective. There is no guarantee that any product will be approved in the sought-after indication. Please click here to view the full EMD Serono pipeline.

DNA Damage Response (DDR)

Tuvusertib (M1774)​

Tuvusertib is an ATR (ataxia telangiectasia and Rad3 related kinase) inhibitor under clinical investigation in patients with solid tumors.

 

Learn More about Tuvusertib



Lartesertib (M4076)​

Lartesertib is an ATM (ataxia telangiectasia mutated kinase) inhibitor under clinical investigation in patients with solid tumors.

 

Learn More about lartesertib

Antibody Drug Conjugates (ADCs)

M9140​

M9140 is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) ADC under clinical investigation in patients with solid tumors.

 

Learn More about M9140

Immuno-oncology

Avelumab​

Avelumab is an anti-PD-L1 antibody under clinical investigation in patients with solid tumors.

 

Learn More about Avelumab




M6223​

M6223 is an anti-TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains) antibody under clinical investigation in patients with solid tumors.
 

Learn More about M6223